- NAFDAC has refused to discontinue hydroxychloroquine trials for coronavirus patients
- The director-general of NAFDAC, Mojisola Adeyeye, made the declaration on Tuesday, May 26
- Adeyeye said that the pill has proven strong enough to cure the virus at its mild stage
Mojisola Adeyeye, the director-general of the National Agency for Food and Drug Control (NAFDAC) has said that Nigeria will continue with hydroxychloroquine trials for the treatment of COVID-19.
The statement by Adeyeye came after the World Health Organisation ordered the trial to be stopped throughout the globe.
However, the NAFDAC boss said that the pill has proven strong enough to cure coronavirus at its emergent stage, according to data released by the agency, TVC reports.
Adeyeye said: “There is data to prove that hydroxychloroquine worked for many COVID-19 patients. Therefore, we would continue our own clinical trials in Nigeria.
“Hydroxychloroquine has been proved to work at a mild stage. So the potency depends on the severity of the disease in the patient’s body.”
Earlier, Legit.ng reported that as the world faces the herculean task of getting a solution to novel coronavirus, the World Health Organisation (WHO) said it has suspended the "solidarity trial" of hydroxychloroquine for Covid-19 treatment.
The global health agency announced the decision on Monday, May 25, through its director-general, Tedros Ghebreyesus.
Citing the study carried out and published by The Lancet, which had examined the effects of the use of hydroxychloroquine alone or with macrolide, Ghebreyesus in his address said WHO is unable to confirm the effect of chloroquine when used for Covid-19 treatment.
“We were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19.
"Each of these dru'g regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for treatment of COVID-19,” he said.
In an earlier address, Ghebreyesus said that WHO discovered more fatalities were recorded across 400 hospitals in 35 countries where hydroxychloroquine was permitted to use for coronavirus treatment.
He said: “Over 400 hospitals in 35 countries are actively recruiting patients and nearly 3500 patients have been enrolled from 17 countries.
“On Friday, the Lancet published an observational study on hydroxychloroquine and chloroquine and its effects on COVID-19 patients that have been hospitalised."
Coronavirus: Does the Madagascar cure really work? | Legit TV